The world’s first “Vial-to-Harvest” Vaccine manufacturing platform with Linear scalability & ultimate process efficiency.
With decades of developmental efforts & experience in Bioprocess Engineering, we have solved the most critical problems of adherent cell culture processing i.e. 1) Lack of process scalability 2) Efficiency in terms of time to market 3) Affordability in terms of cost reduction in manufacturing process.
At OmniBRx, we have invented a novel bioreactor technology for large-scale biologics / vaccines production and stem-cell therapy use. The technology provides 10X Scalability, 6X efficiency and up to 90% cost reduction during upstream manufacturing processing.
Our patented “CellBRx®️” single-use bioreactors technology is the first-of-its-kind bioreactor devices offering a fully automated and robust platform for vaccine manufacturing with linear scalability of up to 200L bioreactor volume accommodating 1500 m2 of surface area per single-use bioreactor. The proprietary DBR technology employs parallel discs stacked on multiple shafts and the intermingling rotational arrangement of the discs ensures efficient mixing and homogeneity throughout the cell carrier matrix.
With the integrated seed-train development protocol, the technology becomes the first ever close-circuit fully-automated Vial-to-Harvest production platform. The CellBRx bioreactors can grow cells in high densities and recover them efficiently with complete end-to-end process automation.